The COVID-19 pandemic will not have a significant impact on completion of the Phase III CARDINAL trial of bardoxolone for CKD caused by Alport syndrome.- Reata Pharma
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest